Healthcare May 10, 2022 09:32 PM (GMT+8) · EqualOcean
On May 10, Pfizer and biohaven Pharmaceutical (hereinafter referred to as "biohaven") announced that the two companies had reached a clear agreement. According to the agreement, Pfizer would acquire biohaven, the manufacturer of nurtec ODT, for a total of about US $11.6 billion. Nurtec ODT is an innovative dual effect migraine therapy approved in the United States for acute treatment and paroxysmal prevention of migraine in adults. According to the terms of the agreement, the proposed transaction includes the acquisition of biohaven's calcitonin gene-related peptide (CGRP) project, such as rimegepant (US trade name: nurtec ODT; EU trade name: vydura); Zavegepant - intended for acute intranasal spray treatment of migraine, and is being developed as an oral soft capsule for the prevention of chronic migraine; And five preclinical CGRP portfolios. It is reported that biohaven plans to submit a new drug application for zavegepant to the FDA in the second quarter of 2022.